CodexisCDXS
Market Cap: $194M
About: Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.
Employees: 174
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
106% more call options, than puts
Call options by funds: $35K | Put options by funds: $17K
2.84% more ownership
Funds ownership: 76.68% [Q1] → 79.52% (+2.84%) [Q2]
8% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 40
4% less funds holding
Funds holding: 123 [Q1] → 118 (-5) [Q2]
8% less capital invested
Capital invested by funds: $188M [Q1] → $174M (-$14.1M) [Q2]
28% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 18
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Cantor Fitzgerald Kristen Kluska 59% 1-year accuracy 48 / 81 met price target | 301%upside $11 | Overweight Reiterated | 29 Aug 2024 |
Cantor Fitzgerald Kristen Kluska 59% 1-year accuracy 48 / 81 met price target | 301%upside $11 | Overweight Reiterated | 9 Aug 2024 |
Financial journalist opinion
Based on 6 articles about CDXS published over the past 30 days